To our knowledge, this is the first study reporting the utility of GEP to predict not only the ORR and PFS but also OS benefits in response to the combination of an anti-VEGF therapy plus an ICI therapy in patients with MM. Here, VEGFA is linked to Miyoshi myopathy.